DENVER, Colo., Sept 13, 2023 (www.247marketnews.com)-
Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon Disease AND Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock– Rocket Pharma (NASDAQ: RCKT) is trading at $19.85, up $4.56 (+29.82%), on 4.91M, on 21.71M shares traded.
Workhorse Receives IRS Approval for Commercial Clean Vehicle Credit– Workhorse Group (NASDAQ: WKHS) is trading at $0.75, up $0.12 (+18.11%), on 11.28M, on 7.03M shares traded.
Hoth Therapeutics Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia– Hoth Therapeutics (NASDAQ: HOTH) is trading at $3.01, up $0.33 (+12.31%), on 3.92M shares traded.
Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%– Mainz Biomed BV (NASDAQ: MYNZ) is trading at $3.96, up $0.30 (+8.20%), on2.9M shares traded.
Almost all of today’s momentum movers published announcements yesterday.
Avalo Therapeutics (NASDAQ:AVTX) is trading at $0.21, up $0.09 (+73.60%), on 119.11M shares traded.
Zyversa Therapeutics (NASDAQ:ZVSA) is trading at $0.19, up $0.06 (+50.04%), on 34.3M shares traded.
Axcella Health (NASDAQ:AXLA) is trading at $1.47, up $0.33 (+28.51%), on 36.2M shares traded.
Super League Gaming (NASDAQ:SLE) is trading at $2.33, up $0.38 (+19.55%), on 9.36M shares traded.
Connect with 24/7 Market News:
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community.
DISCLOSURE: 24/7 Market News Inc. (247), owns and operates www.247marketnews.com is a third-party publisher and news release service provider which disseminates corporate news electronically through multiple online media platforms. 247 is NOT an affiliate with any of the companies mentioned in our reports. 247 is a news distribution service and is not registered with FINRA or any other professional licensing service. 247 is not an analyst, broker dealer or advisor, and holds no such licenses. 247 may NOT offer to buy, sell, or hold any security. 247 Venture Beats, and Breakfast bits and any other corporate profiles will NEVER be a solicitation or recommendation of any kind, of any security mentioned. The materials in all our releases are intended to be for informational purposes only and should never be considered research or due diligence on any company mentioned. All readers are encouraged to perform standard due diligence by reading the company’s filings at SEC.gov. Readers should consult their broker or licensed professional before investing in any company. All materials in this release are based on publicly available statements made by the companies. 247 is not liable for any investment decisions made by any readers or subscribers. Any investment could result in you losing all your money from investing in any stock. 247’s editor owns no shares of $LSDI and will not trade in the stock. Publisher has been paid to write and send relevant information concerning Lucy Scientific Discovery Inc. to interested readers. 24/7 has been paid up to twenty-five thousand dollars per week by Totaligent for continuous updates and coverage over the next three months 24/7 will use also be using Totaligent’s financial marketing tools and platform. Editors are paid to put a best-case scenario profile out to the investing public. This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and 247 undertakes no obligation to update such statements.
For more information visit https://www.247marketnews.com/lsdi-lucy-scientific-discovery/